As the current flu season progresses, health officials report that while flu cases may have peaked, infection rates remain alarmingly high. Recent data indicates that over one in four flu tests are returning positive results, underscoring the ongoing threat posed by this seasonal virus. The Centers for Disease Control and Prevention (CDC) has identified that Influenza A strains are still the predominant cause of illness.
According to the CDC, an estimated 19,000 individuals, including 86 children, have succumbed to the flu so far this season. This alarming statistic highlights the severity of the ongoing outbreak. Although the overall burden of illness appears to show signs of stabilization, experts caution that the end of flu season is still months away.
Vaccination efforts this year have faced challenges. The CDC reported a significant decrease in flu vaccine administration compared to the previous year, with 702,000 fewer doses and approximately 4.2 million fewer doses given. As of February 1, around 36.5 million doses were administered in pharmacies for adults, while about 20.6 million doses were given in doctor's offices.
Despite the lower vaccination numbers, the current flu vaccine demonstrates a favorable match against circulating strains. This year's formulation has a 51% match for the Influenza A (H3N2) strain, which accounts for nearly half of all cases detected this season. Furthermore, it is a 100% match for both the Influenza A (H1N1) strain and Influenza B strain, which combined make up almost 51% of reported infections.
Dr. Jonathan L. Temte emphasized the importance of vaccination, stating, “While we are still in the influenza season, I recommend getting vaccinated, even if one has already had a case of influenza.” He further noted that “influenza season is composed of both influenza A and influenza B,” indicating that individuals are still at risk for additional infections as the season continues.
The flu vaccine is estimated to be about 40% effective in preventing laboratory-confirmed respiratory infections among individuals seen in clinical settings. Dr. Temte added, “On average, influenza vaccines are about 40% effective in preventing laboratory confirmed, respiratory infections in individuals seen in clinical settings.” This effectiveness rate is essential information for those considering whether to receive the vaccine.
Despite the challenges posed by fluctuating infection rates, current analyses suggest that the vaccine is well-suited to combat this year’s strains. Dr. Temte explained, “If you do the math, we end up with greater than a 75% match,” indicating that those who receive the vaccine can expect reasonable protection against prevalent strains.
However, health experts warn that influenza viruses continue to evolve, similar to how COVID-19 has adapted over time. Scientists actively monitor and study these changes to predict which strains will circulate in future seasons.
The FDA's official guidance encourages individuals to receive flu shots, emphasizing their protective benefits against both influenza A and B. Health officials advocate for vaccination now, as it will offer protection over the remaining one to two months of the flu season.
Dr. Temte reiterated the unpredictable nature of influenza outbreaks, stating, “Although we have likely had our peak of influenza A in the U.S., 40% to 45% of influenza A cases are yet to come.” This statement serves as a reminder that vigilance remains crucial as the season unfolds.
Leave a Reply